Sarepta (SRPT) Appoints Henri Termeer As Advisor To The Company

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced Henri Termeer, industry leader and former CEO of Genzyme, will be a key advisor to the Company.

"I am honored to have Henri Termeer, a pioneer of rare disease companies, serve as an advisor as we seek FDA approval for our lead product candidate and build a rare disease organization," said Edward Kaye, M.D., Sarepta's interim chief executive officer and chief medical officer.

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.